We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

MorphoSys Announces Acquisition of Sloning


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces Acquisition of Sloning"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
MorphoSys AG announces the acquisition of the private German company Sloning BioTechnology GmbH, a biotechnology company developing new methods of synthetic biology. The transaction will make MorphoSys the sole source of Sloning’s Slonomics technology, which can improve the assembly and quality of protein libraries.

By integrating Slonomics into its existing antibody technology platform, MorphoSys expects to improve the generation of drug candidates such that one in every two projects started reaches clinical development. The technology will also be used to accelerate the generation of both therapeutic and diagnostic antibodies. Sloning’s shareholders received a one-off EUR 19 million cash payment upon signing.

“This acquisition secures our position at the forefront of antibody technology,” commented Dr Simon Moroney, Chief Executive Officer of MorphoSys AG. “Sloning’s technology is the most powerful method available for assembling protein libraries and has been proven to deliver superior products for a range of applications. We plan to use it to generate optimized antibodies much faster than can be done today and also to gain access to antibodies that simply can’t be made with current technologies.”

Sloning’s patented core technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre-determined positions. This technology opens the way to a new and flexible approach to generating optimized proteins, such as antibodies.

“Current antibody generation technologies use an initial repertoire, which largely determines the properties of the resulting antibody. We intend to use Slonomics as the basis of a fundamentally different approach, which will rapidly test multiple generations of antibodies, equivalent to screening many billions of molecules, to isolate the best possible candidate,” stated Dr Marlies Sproll, Chief Scientific Officer of MorphoSys AG. “We expect to shorten the time needed to generate an antibody drug candidate by a third and even more importantly, to increase the proportion of programs reaching clinical development to 50 per cent.”

“We believe that the two companies’ technology portfolios and extensive expertise will lead to superior therapeutic, diagnostic and industrial products,” commented the Chief Executive Officer of Sloning, Dr Heinz Schwer, who will join MorphoSys, becoming a member of the senior management team.
Advertisement